Original language | English |
---|---|
Journal | ESMO Open |
Volume | 5 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- editorial
- age
- Article
- cancer growth
- cancer immunotherapy
- cancer palliative therapy
- cancer patient
- cancer screening
- cancer therapy
- caregiver
- coronavirus disease 2019
- cytokine storm
- differential diagnosis
- European Medicines Agency
- evidence based practice
- follow up
- Food and Drug Administration
- health care personnel
- hospital admission
- human
- infection risk
- Italy
- malignant neoplasm
- medical oncologist
- pandemic
- risk factor
- telemedicine
- terminal care
- therapy delay
- treatment interruption
- virus pneumonia
- virus transmission
- Betacoronavirus
- China
- Coronavirinae
- Coronavirus infection
- oncologist
- SARS coronavirus
- Coronavirus
- Coronavirus Infections
- Humans
- Oncologists
- Pandemics
- Pneumonia, Viral
- SARS Virus
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective. / Lambertini, M.; Toss, A.; Passaro, A.; Criscitiello, C.; Cremolini, C.; Cardone, C.; Loupakis, F.; Viscardi, G.; Meattini, I.; Dieci, M.V.; Ferrara, R.; Giusti, R.; Maio, M.D.
In: ESMO Open, Vol. 5, No. 2, 2020.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective
AU - Lambertini, M.
AU - Toss, A.
AU - Passaro, A.
AU - Criscitiello, C.
AU - Cremolini, C.
AU - Cardone, C.
AU - Loupakis, F.
AU - Viscardi, G.
AU - Meattini, I.
AU - Dieci, M.V.
AU - Ferrara, R.
AU - Giusti, R.
AU - Maio, M.D.
N1 - Cited By :75 Export Date: 3 March 2021 Correspondence Address: Lambertini, M.; Department of Medical Oncology, Italy; email: matteo.lambertini@unige.it Funding details: Bayer Funding details: Servier Funding details: Amgen Funding details: Roche Italia Funding text 1: Matteo Lambertini acted as consultant for Roche and Lilly, and received speaker honoraria from Roche, Takeda and Theramex outside the submitted work. Angela Toss acted as consultant for Eisai, Roche and Lilly outside the submitted work. Antonio Passaro acted as consultant for AstraZeneca, Agilent/Dako, Bristol-Myers Squibb, Lilly, Merck Sharp & Dohme and Roche. Carmen Criscitiello received speakers’ bureau and had consultancy/advisory role from Lilly, Roche Novartis, and Pfizer outside the submitted work. Chiara Cremolini acted as consultant for Roche, Bayer and Amgen, and received personal fees from Roche, Amgen, Bayer, Servier, and research funding from Merck Serono. Icro Meattini acted as consultant for Roche, Novartis, and Lilly outside the submitted work. Maria Vittoria Dieci acted as consultant for Eli Lilly, Genomic Health and Celgene outside the submitted work. Raffaele Giusti acted as consultant and received speaker honoraria for Roche and Astra Zeneca outside the submitted work. Massimo Di Maio acted as consultant for Eisai, Takeda, Janssen, Astellas, Pfizer and AstraZeneca, outside the submitted work. The other authors declare no conflicts of interests. References: Zhu, N., Zhang, D., Wang, W., A novel coronavirus from patients with pneumonia in China 2019 (2020) N Engl J Med, 382, pp. 727-733; Lu, R., Zhao, X., Li, J., Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding (2020) Lancet, 395, pp. 565-574; World Health Organization, , https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-At-the-media-briefng-on-covid-19-11-march-2020; Istituto Superiore di Sanità, , https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati; Remuzzi, A., Remuzzi, G., Covid-19 and Italy: What next? (2020) Lancet, , [Epub ahead of print: 13 Mar 2020]; (2020) Gazzetta Uffciale della Repubblica Italiana, , https://www.gazzettauffciale.it/eli/gu/2020/03/09/62/sg/pdf; Li, R., Pei, S., Chen, B., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (sars-cov2) (2020) Science, 6, p. eabb3221; Spina, S., Marrazzo, F., Migliari, M., The response of milan's emergency medical system to the covid-19 outbreak in Italy (2020) Lancet, 395, pp. e49-e50; Grasselli, G., Pesenti, A., Cecconi, M., Critical care utilization for the covid-19 outbreak in lombardy Italy: Early experience and forecast during an emergency response (2020) JAMA, , [Epub ahead of print: 13 Mar 2020]; Murthy, S., Gomersall, C.D., Fowler, R.A., Care for critically ill patients with covid-19 (2020) JAMA, , [Epub ahead of print: 11 Mar 2020]; Wu, Z., McGoogan, J.M., Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in China: Summary of a report of 72 314 cases from the chinese center for disease control and prevention (2020) JAMA, , [Epub ahead of print: 13 Mar 2020]; Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2020 (2020) CA Cancer J Clin, 70, pp. 7-30; Kamboj, M., Sepkowitz, K.A., Nosocomial infections in patients with cancer (2009) Lancet Oncol, 10, pp. 589-597; Liang, W., Guan, W., Chen, R., Cancer patients in sars-cov-2 infection: A nationwide analysis in China (2020) Lancet Oncol, 21, pp. 335-337; Xia, Y., Jin, R., Zhao, J., Risk of covid-19 for cancer patients (2020) Lancet Oncol, , [Epub ahead of print: 03 Mar 2020]; Ueda, M., Martins, R., Hendrie, P.C., Managing cancer care during the covid-19 pandemic: Agility and collaboration toward a common goal (2020) J Natl Compr Cancer Netw; Rischio Infettivo da Coronavirus COVID 19: Indicazioni per l'Oncologia da Parte Del Presidente AIOM, Del Presidente Eletto AIOM, Del Presidente CIPOMO e Del Presidente COMU, , https://www.aiom.it/wp-content/uploads/2020/03/20200313-COVID-19-indicazioni-AIOM-CIPOMO-COMU.pdf; Mehta, P., McAuley, D.F., Brown, M., Covid-19: Consider cytokine storm syndromes and immunosuppression (2020) Lancet, , [Epub ahead of print: 16 Mar 2020]; Francesco, C., Pettke, A., Michele, B., Managing covid-19 in the oncology clinic and avoiding the distraction effect (2020) Ann Oncol, , [Epub ahead of print: 19 Mar 2020]; Hollander, J.E., Carr, B.G., Virtually perfect? Telemedicine for covid-19 (2020) N Engl J Med, , [Epub ahead of print: 11 Mar 2020]; Food and Drug Administration (FDA), , https://www.fda.gov/media/136238/download; European Medicines Agency (EMA), , https://www.ema.europa.eu/en/news/guidance-sponsors-how-manage-clinical-trials-during-covid-19-pandemi; Agenzia Italiana Del Farmaco (AIFA), , https://www.aifa.gov.it/documents/20142/871583/Comunicato-gestione-studi-clinici-in-emergenza-COVID-19-EN-12.03.2020.pdf/ee1f33e3-bb3e-9ce9-2a93-b33e88eea94d
PY - 2020
Y1 - 2020
KW - editorial
KW - age
KW - Article
KW - cancer growth
KW - cancer immunotherapy
KW - cancer palliative therapy
KW - cancer patient
KW - cancer screening
KW - cancer therapy
KW - caregiver
KW - coronavirus disease 2019
KW - cytokine storm
KW - differential diagnosis
KW - European Medicines Agency
KW - evidence based practice
KW - follow up
KW - Food and Drug Administration
KW - health care personnel
KW - hospital admission
KW - human
KW - infection risk
KW - Italy
KW - malignant neoplasm
KW - medical oncologist
KW - pandemic
KW - risk factor
KW - telemedicine
KW - terminal care
KW - therapy delay
KW - treatment interruption
KW - virus pneumonia
KW - virus transmission
KW - Betacoronavirus
KW - China
KW - Coronavirinae
KW - Coronavirus infection
KW - oncologist
KW - SARS coronavirus
KW - Coronavirus
KW - Coronavirus Infections
KW - Humans
KW - Oncologists
KW - Pandemics
KW - Pneumonia, Viral
KW - SARS Virus
U2 - 10.1136/esmoopen-2020-000759
DO - 10.1136/esmoopen-2020-000759
M3 - Article
VL - 5
JO - ESMO Open
JF - ESMO Open
SN - 2059-7029
IS - 2
ER -